How Glycosaminoglycans Change with Age
Glycosaminoglycans are a class of sulfated, negatively charged polysaccharides that decline in content and shift in sulfation pattern with age. This page summarises laboratory and clinical evidence on age-related changes
What are glycosaminoglycans and how do they change with age?
Glycosaminoglycans (GAGs) are a family of linear, sulfated polysaccharides built from repeating disaccharide units. Common members include heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic acid. With age, total GAG content in many tissues declines, and the sulfation pattern and chain length of remaining GAGs shift. These changes are most documented in skin, cartilage and vascular extracellular matrix (ECM). The evidence below draws on human cell culture, animal models, clinical trial registries and reviews; where findings are animal-only or in vitro, this is stated.
The work centres on the ECM and its proteoglycans, particularly decorin, syndecan-1 and the glycocalyx, and on signalling through the kisspeptin receptor (KISS1R) and growth-factor pathways that regulate GAG synthesis.
Research Studies
Kisspeptin-10 and glycosaminoglycan/decorin content in human cardiac fibroblasts
In human cardiac fibroblast cultures, kisspeptin-10 (KiSS-10) was tested for its effect on glycosaminoglycan and decorin levels. The study used a human cardiac fibroblast cell line and measured GAGs by the Farndale method and decorin secretion by ELISA. The aim was to determine whether KiSS-10 influences these ECM components and to identify the signalling mechanism, with and without signalling inhibitors [1]. This is an in vitro finding; it does not establish what happens in intact human heart tissue with age.
GHK peptide and glycosaminoglycan synthesis in skin models
Glycyl-histidyl-lysine (GHK) is a tripeptide studied for topical anti-wrinkle applications. A review reports that GHK can enhance collagen and glycosaminoglycan synthesis, and also increase nerve outgrowth and angiogenesis in preclinical models. Derivatives include GHK-Cu (a copper complex) and Pal-GHK (palmitoylated). The review notes that these are widely used in anti-wrinkle products but discusses advantages and problems of topical delivery [2]. The evidence is largely preclinical; no human dose or outcome is given here.
Chondroitin sulfate in osteoarthritis: real-world study design
Chondroitin sulfate (CS) is a glycosaminoglycan and a major ECM component of proteoglycans. It is classified as a Symptomatic Slow Acting Drug for Osteoarthritis (SYSADOA). A prospective, observational, national study in Poland (TRUST) is designed to describe the burden of osteoarthritis and quality of life in adult patients treated with Structum® (a chondroitin sulfate product) [4]. This is a study protocol; results are not yet reported in the evidence block.
Heparan sulfate and CACIPLIQ20 in epidermolysis bullosa wounds
Epidermolysis bullosa (EB) is a group of inherited disorders causing skin and mucous membrane fragility. A clinical trial (NCT06007235) is evaluating CACIPLIQ20, a product containing heparan sulfate, in wound healing in subjects with EB. The registry entry notes that heparan sulfates are key elements of the ECM and that no treatments have been approved for EB to date [3]. This is an ongoing trial; no efficacy data are provided here.
Glycocalyx degradation and circulating unmeasured ions after cardiopulmonary bypass
A prospective subanalysis embedded in a randomized trial examined whether endothelial glycocalyx degradation is associated with increased circulating unmeasured anions after cardiopulmonary bypass. The hypothesis is that release of polyanionic heparan sulfate fragments from the glycocalyx contributes to this unexplained anionic burden [5]. This is a reference-only finding; it reports an association, not causation, and is not specific to ageing.
GHK-Cu in aesthetic medicine: regenerative potential
A review on GHK-Cu in aesthetic medicine reports that the copper tripeptide has demonstrated regenerative, anti-inflammatory and antioxidant properties in preclinical models, and notes its increasing integration into aesthetic practice [6]. This is a reference-only item; it does not provide human clinical trial data on GAG changes with age.
Proteoglycans in bone metastasis: ECM remodelling and tumour-bone crosstalk
A review discusses proteoglycans as molecular regulators of bone metastasis, focusing on ECM remodelling, tumour-bone crosstalk, dormancy and therapeutic opportunities. It covers breast and prostate cancer metastasis to bone and the role of the bone microenvironment [7]. This is a reference-only item; it is not about normal ageing but illustrates how GAG/proteoglycan changes can alter tissue behaviour.
Syndecan-1 and intestinal mucosal homeostasis in inflammatory bowel disease
A study reports that intestinal epithelial syndecan-1 (SDC1), a heparan sulfate proteoglycan, maintains mucosal homeostasis in inflammatory bowel disease by enhancing Faecalibacterium prausnitzii biofilm formation [8]. This is a reference-only finding; it links a specific proteoglycan to microbiome interactions, not directly to age-related GAG decline.
Comparison of GAG-related findings by model
| Compound/Pathway | Model | Key observation | Citation |
|---|---|---|---|
| Kisspeptin-10 | Human cardiac fibroblast cell line (in vitro) | Regulates GAG and decorin content; mechanism probed with inhibitors | [1] |
| GHK peptide | Preclinical models (review) | Enhances collagen and GAG synthesis; also nerve outgrowth and angiogenesis | [2] |
| Chondroitin sulfate (Structum®) | Human observational study (protocol) | Describes OA burden and quality of life; no results yet | [4] |
| Heparan sulfate (CACIPLIQ20) | Human clinical trial (ongoing) | Evaluated for wound healing in epidermolysis bullosa | [3] |
| Glycocalyx heparan sulfate | Human prospective subanalysis | Degradation associated with unmeasured anions after bypass | [5] |
| GHK-Cu | Preclinical models (review) | Regenerative, anti-inflammatory, antioxidant properties | [6] |
| Proteoglycans (general) | Review (cancer models) | Regulate bone metastasis and ECM remodelling | [7] |
| Syndecan-1 | IBD models (reference only) | Maintains mucosal homeostasis via F. prausnitzii biofilm | [8] |
If you are reading this for personal health reasons
The compounds and materials discussed on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or treatment recommendations. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures. https://europepmc.org/article/PMC/PMC13437659
- [2] Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. https://europepmc.org/article/PMC/PMC11830136
- [3] CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa. https://clinicaltrials.gov/study/NCT06007235
- [4] Study on Structum® in Adult Patients With Osteoarthritis (TRUST). https://clinicaltrials.gov/study/NCT06623773
- [5] Glycocalyx degradation is associated with increased circulating unmeasured ions after cardiopulmonary bypass. https://pubmed.ncbi.nlm.nih.gov/42667737/
- [6] The Regenerative Potential of GHK-Cu in Aesthetic Medicine. https://pubmed.ncbi.nlm.nih.gov/42619529/
- [7] Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities. https://pubmed.ncbi.nlm.nih.gov/42509832/
- [8] Intestinal epithelial Syndecan-1 maintains mucosal homeostasis in inflammatory bowel disease by enhancing Faecalibacterium prausnitzii biofilm formation. https://europepmc.org/article/PMC/PMC13138079